Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Batefenterol - Innoviva

Next Previous
X
Search
Drug Profile

Batefenterol - Innoviva

Alternative Names: '081; 961081; Batefenterol succinate; GSK-961081; GSK-961081A; GSK-961081D; TD-5959

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theravance
  • Developer GSK
  • Class Biphenyl compounds; Bronchodilators; Carbamates; Carboxylic acids; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 22 Apr 2021 Discontinued - Phase-I for Chronic obstructive pulmonary disease (Combination therapy, In volunteers) in United Kingdom (Inhalation)
  • 22 Apr 2021 Discontinued - Phase-II for Chronic obstructive pulmonary disease in United Kingdom, South Africa, Russia, Sweden, Romania, Netherlands, New Zealand, Thailand, Slovakia, Estonia, Germany, Estonia, USA, and Ukraine (Inhalation)
  • 01 Jul 2016 GlaxoSmithKline completes a phase II trial for Chronic obstructive pulmonary disease in USA, Germany and South Africa (NCT02570165)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top